HCW Biologics Advances TGF-β/IL-15 Cancer Immunotherapy
Miramar, Fla. – August 25, 2026 HCW Biologics announced new findings supporting its TGF-β trap and IL-15 fusion moiety...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Miramar, Fla. – August 25, 2026 HCW Biologics announced new findings supporting its TGF-β trap and IL-15 fusion moiety...
MIRAMAR, Fla., July 23, 2026 HCW Biologics Inc. announced a significant advancement in the development of its proprietary tetravalent...
